HomeAI · summaries
Storia in 17 fonti
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the strongest weight loss data yet in Phase 3 trial in a pure obesity population.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As…
- ·
statnews.com
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
